Reform of litigation funding and implications for life sciences companies | Practical Law

Reform of litigation funding and implications for life sciences companies | Practical Law

Various reforms have been proposed to the litigation funding regime in England and Wales. This article examines the nature of the reforms and other proposals, conditional fee agreements, after the event insurance, damages based agreements, third party funding/litigation funding, qualified one-way cost shifting, liberalisation of the legal market and the impact on pharmaceutical claims.

Reform of litigation funding and implications for life sciences companies

Practical Law UK Articles 6-518-1506 (Approx. 8 pages)

Reform of litigation funding and implications for life sciences companies

by Freshfields Bruckhaus Deringer LLP and Mira Raja, Freshfields Bruckhaus Deringer LLP
Law stated as at 01 Nov 2011 • United Kingdom
Various reforms have been proposed to the litigation funding regime in England and Wales. This article examines the nature of the reforms and other proposals, conditional fee agreements, after the event insurance, damages based agreements, third party funding/litigation funding, qualified one-way cost shifting, liberalisation of the legal market and the impact on pharmaceutical claims.
This article is part of the PLC multi-jurisdictional guide to life sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifesciences-mjg.